Proposed Data Collection Submitted for Public Comment and Recommendations, 71806-71807 [2015-29274]
Download as PDF
71806
Federal Register / Vol. 80, No. 221 / Tuesday, November 17, 2015 / Notices
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
[FR Doc. 2015–29273 Filed 11–16–15; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–16–1019; Docket No. CDC–2015–
0102]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing efforts to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies to take this opportunity to
comment on proposed and/or
continuing information collections, as
required by the Paperwork Reduction
Act of 1995.
This notice invites comment on
Integrating Community Pharmacists and
Clinical Sites for Patient-Centered HIV
Care. CDC is requesting a 3-year
approval for revision to the previously
approved project to administer a staff
communication questionnaire for
medical providers in order to determine
how and if the model program improves
patient outcomes through improved
communication and collaboration
between patients’ clinical providers and
pharmacists.
DATES: Written comments must be
received on or before January 19, 2016.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2015–
0102 by any of the following methods:
• Federal eRulemaking Portal:
Regulation.gov. Follow the instructions
for submitting comments.
• Mail: Leroy A. Richardson,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE., MS–
D74, Atlanta, Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to Regulations.gov, including any
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:14 Nov 16, 2015
Jkt 238001
personal information provided. For
access to the docket to read background
documents or comments received, go to
Regulations.gov.
Please note: All public comment
should be submitted through the
Federal eRulemaking portal
(Regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact the Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE., MS–D74, Atlanta,
Georgia 30329; phone: 404–639–7570;
Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology; and (e) estimates of capital
or start-up costs and costs of operation,
maintenance, and purchase of services
to provide information. Burden means
the total time, effort, or financial
resources expended by persons to
generate, maintain, retain, disclose or
provide information to or for a Federal
agency. This includes the time needed
to review instructions; to develop,
acquire, install and utilize technology
and systems for the purpose of
collecting, validating and verifying
information, processing and
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information, to search
data sources, to complete and review
the collection of information; and to
transmit or otherwise disclose the
information.
Proposed Project
Integrating Community Pharmacists
and Clinical Sites for Patient-Centered
HIV Care (OMB 0920–1019, expires 8/
31/2018)—Revision—National Center
for HIV/AIDS, Viral Hepatitis, STD, and
TB Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
Medication Therapy Management
(MTM) is a group of pharmacist
provided services that is independent
of, but can occur in conjunction with,
provision of medication. Medication
Therapy Management encompasses a
broad range of professional activities
and cognitive services within the
licensed pharmacists’ scope of practice
and can include monitoring prescription
filling patterns and timing of refills,
checking for medication interactions,
patient education, and monitoring of
patient response to drug therapy.
HIV-specific MTM programs have
demonstrated success in improving HIV
medication therapy adherence and
persistence. While MTM programs have
be shown to be effective in increasing
medication adherence for HIV-infected
persons, no MTM programs have been
expanded to incorporate primary
medical providers in an effort to
establish patient-centered HIV care. To
address this problem, CDC has entered
into a public-private partnership with
Walgreen Company (a.k.a. Walgreens
pharmacies, a national retail pharmacy
chain) to develop and implement a
model of HIV care that integrates
community pharmacists with primary
medical providers for patient-centered
HIV care. The model program will be
implemented in ten sites and will
provide patient-centered HIV care for
approximately 1,000 persons.
The patient-centered HIV care model
will include the core elements of MTM
as well as additional services such as
individualized medication adherence
counseling, active monitoring of
prescription refills and active
collaboration between pharmacists and
medical clinic providers to identify and
resolve medication related treatment
problems such as treatment
effectiveness, adverse events and poor
adherence. The expected outcomes of
the model program are increased
retention in HIV care, adherence to HIV
E:\FR\FM\17NON1.SGM
17NON1
71807
Federal Register / Vol. 80, No. 221 / Tuesday, November 17, 2015 / Notices
medication therapy and viral load
suppression.
On May 16, 2014 OMB approved the
collection of standardized information
from ten project sites over the three-year
project period and one retrospective
data collection during the first year of
the three-year project period. The
retrospective data collection will
provide information about clients’
baseline characteristics prior to
participation in the model program
which is needed to compare outcomes
before and after program
implementation. On August 17, 2015
OMB approved the conduct of key
informant interviews with program
clinic and pharmacy staff in order to
evaluate the program processes,
administration of a staff communication
questionnaire, and OMB approved the
collection of time and cost data to be
used to estimate the cost of the model
program.
CDC seeks approval to administer a
staff communication questionnaire for
medical providers in order to determine
program activities, will be collected by
program. Qualitative data will be
gathered from program staff through inperson or telephone interviews and
through a questionnaire to program
pharmacy staff and a separate
questionnaire to program clinic staff.
The data collection will allow CDC to
conduct continuous program
performance monitoring which includes
identification of barriers to program
implementation, solutions to those
barriers, and documentation of client
health outcomes. Performance
monitoring will allow the model
program to be adjusted, as needed, in
order to develop a final implementation
model that is self-sustaining and which
can be used to establish similar
collaborations in a variety of clinical
settings. Collection of cost data will
allow for the cost of the program to be
estimated.
There is no cost to participants other
than their time. The total estimated
annualized burden hours are 6,043.
how and if the model program improves
patient outcomes through improved
communication and collaboration
between patients’ clinical providers and
pharmacists. The staff communication
questionnaire for medical providers will
be administered twice to program clinic
staff. The staff communication
questionnaire for medical providers is
different from the previously improved
staff communication questionnaire; the
staff communication questionnaire for
medical providers will be administered
to program clinic staff whereas the staff
communication questionnaire will be
administered to program pharmacy staff.
Pharmacy, laboratory, and medical
data will be collected through
abstraction of all participant clients’
pharmacy and medical records.
Pharmacy, laboratory and medical data
are needed to monitor retention in care,
adherence to therapy, viral load
suppression and other health outcomes.
Program specific data, such as the
number of MTM elements completed
per project site and time spent on
ESTIMATED ANNUALIZED BURDEN HOURS
Average
burden per
response
(in hours)
Number of
responses per
respondent
Number of
respondents
Total burden
(in hours)
Type of respondent
Form name
Clinic Data Manager .........................
Pharmacist ........................................
10
10
3
3
30/60
30/60
15
15
10
100
5/60
83
10
10
10
60
100
400
400
2
1
30/60
30/60
30/60
1,000
2,000
2,000
60
30
40
2
2
30/60
30/60
30
40
Clinic staff .........................................
Pharmacy staff ..................................
Project clinic characteristics form ....
Project pharmacy characteristics
form.
*Patient Demographic Information
form.
*Initial patient information form ........
Quarterly patient information form ...
Pharmacy record abstraction form ...
Interviewer data collection worksheet.
Staff communication questionnaire ..
Staff communication questionnaire
for medical providers.
Clinic cost form ................................
Pharmacy cost form .........................
20
20
2
2
10
10
400
400
Total ...........................................
...........................................................
........................
........................
........................
6,043
Clinic Data Manager .........................
Clinic Data Manager .........................
Clinic Data Manager .........................
Pharmacist ........................................
Key informants ..................................
Project staff (pharmacists) ................
Project staff (medical providers) .......
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2015–29274 Filed 11–16–15; 8:45 am]
Board of Scientific Counselors,
National Center for Injury Prevention
and Control: Notice of Charter Renewal
mstockstill on DSK4VPTVN1PROD with NOTICES
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the Board
of Scientific Counselors, National
Center for Injury Prevention and
Control, Centers for Disease Control and
Prevention (CDC), Department of Health
VerDate Sep<11>2014
18:14 Nov 16, 2015
Jkt 238001
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
and Human Services (HHS), has been
renewed for a 2-year period through
November 5, 2017.
For information, contact Gwendolyn
Cattledge, Ph.D., Designated Federal
Officer, Board of Scientific Counselors,
National Center for Injury Prevention
and Control, CDC, HHS, 1600 Clifton
Road NE., M/S F63, Atlanta, Georgia
30329–4027, Telephone 770/488–4655.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
E:\FR\FM\17NON1.SGM
17NON1
Agencies
[Federal Register Volume 80, Number 221 (Tuesday, November 17, 2015)]
[Notices]
[Pages 71806-71807]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-29274]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-16-1019; Docket No. CDC-2015-0102]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing efforts to reduce public burden and maximize the
utility of government information, invites the general public and other
Federal agencies to take this opportunity to comment on proposed and/or
continuing information collections, as required by the Paperwork
Reduction Act of 1995.
This notice invites comment on Integrating Community Pharmacists
and Clinical Sites for Patient-Centered HIV Care. CDC is requesting a
3-year approval for revision to the previously approved project to
administer a staff communication questionnaire for medical providers in
order to determine how and if the model program improves patient
outcomes through improved communication and collaboration between
patients' clinical providers and pharmacists.
DATES: Written comments must be received on or before January 19, 2016.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2015-
0102 by any of the following methods:
Federal eRulemaking Portal: Regulation.gov. Follow the
instructions for submitting comments.
Mail: Leroy A. Richardson, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE., MS-D74, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name and
Docket Number. All relevant comments received will be posted without
change to Regulations.gov, including any personal information provided.
For access to the docket to read background documents or comments
received, go to Regulations.gov.
Please note: All public comment should be submitted through the
Federal eRulemaking portal (Regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact the Information Collection Review Office,
Centers for Disease Control and Prevention, 1600 Clifton Road NE., MS-
D74, Atlanta, Georgia 30329; phone: 404-639-7570; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
Federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; (d) ways to
minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology; and (e) estimates of capital or start-
up costs and costs of operation, maintenance, and purchase of services
to provide information. Burden means the total time, effort, or
financial resources expended by persons to generate, maintain, retain,
disclose or provide information to or for a Federal agency. This
includes the time needed to review instructions; to develop, acquire,
install and utilize technology and systems for the purpose of
collecting, validating and verifying information, processing and
maintaining information, and disclosing and providing information; to
train personnel and to be able to respond to a collection of
information, to search data sources, to complete and review the
collection of information; and to transmit or otherwise disclose the
information.
Proposed Project
Integrating Community Pharmacists and Clinical Sites for Patient-
Centered HIV Care (OMB 0920-1019, expires 8/31/2018)--Revision--
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
(NCHHSTP), Centers for Disease Control and Prevention (CDC).
Background and Brief Description
Medication Therapy Management (MTM) is a group of pharmacist
provided services that is independent of, but can occur in conjunction
with, provision of medication. Medication Therapy Management
encompasses a broad range of professional activities and cognitive
services within the licensed pharmacists' scope of practice and can
include monitoring prescription filling patterns and timing of refills,
checking for medication interactions, patient education, and monitoring
of patient response to drug therapy.
HIV-specific MTM programs have demonstrated success in improving
HIV medication therapy adherence and persistence. While MTM programs
have be shown to be effective in increasing medication adherence for
HIV-infected persons, no MTM programs have been expanded to incorporate
primary medical providers in an effort to establish patient-centered
HIV care. To address this problem, CDC has entered into a public-
private partnership with Walgreen Company (a.k.a. Walgreens pharmacies,
a national retail pharmacy chain) to develop and implement a model of
HIV care that integrates community pharmacists with primary medical
providers for patient-centered HIV care. The model program will be
implemented in ten sites and will provide patient-centered HIV care for
approximately 1,000 persons.
The patient-centered HIV care model will include the core elements
of MTM as well as additional services such as individualized medication
adherence counseling, active monitoring of prescription refills and
active collaboration between pharmacists and medical clinic providers
to identify and resolve medication related treatment problems such as
treatment effectiveness, adverse events and poor adherence. The
expected outcomes of the model program are increased retention in HIV
care, adherence to HIV
[[Page 71807]]
medication therapy and viral load suppression.
On May 16, 2014 OMB approved the collection of standardized
information from ten project sites over the three-year project period
and one retrospective data collection during the first year of the
three-year project period. The retrospective data collection will
provide information about clients' baseline characteristics prior to
participation in the model program which is needed to compare outcomes
before and after program implementation. On August 17, 2015 OMB
approved the conduct of key informant interviews with program clinic
and pharmacy staff in order to evaluate the program processes,
administration of a staff communication questionnaire, and OMB approved
the collection of time and cost data to be used to estimate the cost of
the model program.
CDC seeks approval to administer a staff communication
questionnaire for medical providers in order to determine how and if
the model program improves patient outcomes through improved
communication and collaboration between patients' clinical providers
and pharmacists. The staff communication questionnaire for medical
providers will be administered twice to program clinic staff. The staff
communication questionnaire for medical providers is different from the
previously improved staff communication questionnaire; the staff
communication questionnaire for medical providers will be administered
to program clinic staff whereas the staff communication questionnaire
will be administered to program pharmacy staff.
Pharmacy, laboratory, and medical data will be collected through
abstraction of all participant clients' pharmacy and medical records.
Pharmacy, laboratory and medical data are needed to monitor retention
in care, adherence to therapy, viral load suppression and other health
outcomes. Program specific data, such as the number of MTM elements
completed per project site and time spent on program activities, will
be collected by program. Qualitative data will be gathered from program
staff through in-person or telephone interviews and through a
questionnaire to program pharmacy staff and a separate questionnaire to
program clinic staff.
The data collection will allow CDC to conduct continuous program
performance monitoring which includes identification of barriers to
program implementation, solutions to those barriers, and documentation
of client health outcomes. Performance monitoring will allow the model
program to be adjusted, as needed, in order to develop a final
implementation model that is self-sustaining and which can be used to
establish similar collaborations in a variety of clinical settings.
Collection of cost data will allow for the cost of the program to be
estimated.
There is no cost to participants other than their time. The total
estimated annualized burden hours are 6,043.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondent Form name Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
Clinic Data Manager........... Project clinic 10 3 30/60 15
characteristics
form.
Pharmacist.................... Project pharmacy 10 3 30/60 15
characteristics
form.
Clinic Data Manager........... *Patient 10 100 5/60 83
Demographic
Information
form.
Clinic Data Manager........... *Initial patient 10 100 1 1,000
information
form.
Clinic Data Manager........... Quarterly 10 400 30/60 2,000
patient
information
form.
Pharmacist.................... Pharmacy record 10 400 30/60 2,000
abstraction
form.
Key informants................ Interviewer data 60 2 30/60 60
collection
worksheet.
Project staff (pharmacists)... Staff 30 2 30/60 30
communication
questionnaire.
Project staff (medical Staff 40 2 30/60 40
providers). communication
questionnaire
for medical
providers.
Clinic staff.................. Clinic cost form 20 2 10 400
Pharmacy staff................ Pharmacy cost 20 2 10 400
form.
---------------------------------------------------------------------------------
Total..................... ................ .............. .............. .............. 6,043
----------------------------------------------------------------------------------------------------------------
Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2015-29274 Filed 11-16-15; 8:45 am]
BILLING CODE 4163-18-P